Catherine Alix-Panabières, Director of the Laboratory of Rare Human Circulating Cells and Professor of Universities – Hospital Practitioner at Montpellier University Hospital, shared a post by European Alliance for Personalised Medicine (EAPM), adding:
“Interview on LiquidBiopsy at Vision Europe 2030
Delighted to answer to some key questions while I was in Brussels!
Watch the full interview.
Thank you Denis Horgan for organizing these important events.”
Quoting European Alliance for Personalised Medicine (EAPM)‘s post:
“Voices from Vision Europe 2030: Catherine Alix-Panabières on Liquid Biopsy
At Vision Europe 2030, co-funded by the European Union and held in Brussels, Catherine Alix-Panabières shared powerful reflections on the past, present, and future of liquid biopsy in precision oncology.
Professor Panabières is a pioneer in the field, having co-coined the term liquid biopsy in 2010 alongside Professor Klaus Pantel, who also participated as a speaker at the conference. Drawing on more than 26 years of research, she highlights how collaboration, harmonisation, and shared European expertise are essential to accelerate clinical translation and move liquid biopsy into routine medical practice.
She also underlines the growing impact of the European Liquid Biopsy Society (ELBS), now uniting around 100 academic and private institutions across Europe, all working towards improved early cancer detection and more personalised treatments. As Working Group Leader for Dissemination and Education, she stresses the importance of equipping researchers and clinicians with best practices for clinical trials and real-world application.
Her message is clear and optimistic: strong European research networks are key to turning scientific innovation into tangible benefits for patients, shaping a more precise, collaborative, and patient-centred future in cancer care.
Watch the full interview.”
More posts featuring Catherine Alix-Panabières.